European Committee for Treatment & Research in Multiple Sclerosis

Startseite
Schweiz
Basel
European Committee for Treatment & Research in Multiple Sclerosis

The European Committee for Treatment & Research in Multiple Sclerosis - the world's largest organisat

SAVE THE DATE: MSMilan2023, the 9th joint ECTRIMS-ACTRIMS meeting, will be held as a hybrid event on 11–13 October in Milan, Italy

17/11/2025

📢 New in Multiple Sclerosis Journals: A cross-sectional case–control study within the US Network of Pediatric MS Centers - led by Jennifer Graves (UC San Diego & Rady Children's Hospital-San Diego) - found no correlation between epigenetic clocks and telomere length, indicating that these measures reflect distinct and complementary dimensions of biological aging in MS.

Read more here: https://journals.sagepub.com/doi/10.1177/13524585251386217

13/11/2025

🎙️ “There isn’t a part of the patient’s MS journey that isn’t touched by nurses — from diagnosis and treatment to aging and rehabilitation.” — Amy Perrin Ross, MS Specialist Nurse and Program Coordinator, Loyola University Chicago

Nurses are at the centre of MS care — guiding patients, coordinating teams, and translating complex science into meaningful support.

In this special podcast episode, Amy Perrin Ross and Miguel Ángel Cortés from Vall d'Hebron Barcelona Hospital Campus discuss how MS nurses combine listening, leadership, and technology to advance patient-centred care.

🎧 Listen now:

🔹 Spotify: https://bit.ly/4hY4bsQ
🔹 Apple Podcasts: https://apple.co/49RE0Sv
🔹 ECTRIMS Website: https://bit.ly/4nMhRIx

13/11/2025

🚨 Time is running out!

Only two weeks left to apply for the 2025 ECTRIMS Fellowship Programmes — a unique opportunity to advance your career in multiple sclerosis research and care, supported by leading experts in the field.

💡 Why apply?

ECTRIMS offers five exclusive fellowships, each providing an annual stipend of up to €55,000, empowering early-career researchers and clinicians to make a lasting impact in MS research and patient care.

🌍 Who can apply?

We welcome applications from young professionals in MS research and care who meet the programme criteria. Gain valuable insights, expand your professional network, and contribute to the future of the MS community.

📅 Deadline: 1 December 2025, 23:59 CET
📖 Learn more and apply 👉 https://ectrims.eu/fellowships

12/11/2025

Join today our Clinical Case NeuroWebinar!

In this interactive session, our expert panel will explore one of the most intriguing challenges in MS management:
How should we approach treatment when patients remain clinically and radiologically stable, yet show persistently elevated NfL levels?

🧠 Rina Demjaha from Medizinische Universität Graz will open with a detailed case study of a 40-year-old MS patient who remains clinically stable on platform therapy and shows no new MRI activity, yet presents with consistently elevated serum NfL levels — prompting key questions about treatment adequacy.

🔍 Michael Khalil from Medizinische Universität Graz will then guide us through the decision-making process in such complex situations, discussing the implications of persistent NfL elevation and whether continued monitoring or treatment modification is the best course of action.

💬 Participants will have the opportunity to submit questions and engage in a live exchange with our panelists.

📅 12 November 2025
🕕 18:00-19:00 CET

Register for free via myECTRIMS 👉 https://my.ectrims.eu/webinars/110

10/11/2025

👀 New MS : Optic Nerve Assessment in MS

The optic nerve has become the fifth anatomical location in the 2024 revisions of the McDonald criteria for MS. Why is it of particular interest and how can it be assessed?

Read it here: https://ectrims.eu/insights/redefining-diagnostic-boundaries-optic-nerve-assessment-in-ms/

Featured in this month's article:

➡️ Shiv Saidha of Johns Hopkins University tells us, "Almost everybody is familiar with MRI. There is perhaps less familiarity with OCT. OCT is quick, inexpensive, and easy to repeat. With a resolution of approximately 3–5 microns, it provides an almost virtual biopsy of the retina."

➡️ Jeffrey Cohen of Cleveland Clinic Mellen Center for MS Treatment and Research adds, "The visual system is frequently affected in MS. Both the afferent and efferent visual pathways are involved in the disease process. Vision plays a crucial role in daily functioning, and its impairment can have a profound impact on an individual’s ability to work and overall quality of life."

07/11/2025

| Beyond the Congress

Stay connected with the science that shaped this year’s congress. The Best of Slide Deck brings together the most highly rated abstracts—covering clinical aspects, pathogenesis, therapy, imaging & biomarkers, plus a dedicated track on RiMS - Rehabilitation in Multiple Sclerosis.

Accessible anytime via myECTRIMS, our platform that supports continuous learning and collaboration within the MS community.

📥 Discover and share today ➡️ https://my.ectrims.eu/bestofslidedecks

06/11/2025

🚀 Apply now for the 2026 ECTRIMS Fellowship Programmes!
You have until 1 December to send in your application — so there’s still time to perfect it! ➡️ https://ectrims.eu/fellowships

🎓 Clinical Fellowship: Acquire specialised skills, collaborate with academia & industry leaders, and propel your clinical career to new heights.

🎓 Research Fellowship: Lead groundbreaking research, contribute to medical advancements, and become a thought leader in your domain.

🎓 Nurses & AHP Professionals Training: Elevate your expertise, enhance patient care, and open doors to diverse career opportunities.

🎓 MAGNIMS-ECTRIMS Fellowship: Use cutting-edge magnetic resonance techniques to advance your expertise in multiple sclerosis studies.

🎓 MEDEN-ECTRIMS Fellowship: Gain invaluable clinical experience in neuromyelitis optica spectrum disorders ( ) and myelin oligodendrocyte glycoprotein antibody-associated disorder ( ).

05/11/2025

🎥 Discover the future of at !

✨ Session 13: Emergent Therapies in MS & Related Conditions — leading experts share breakthrough findings & next-gen approaches in MS, MOGAD & NMOSD.

▶️ Watch now: https://ectrims-congress.virtual-meeting.org/programme/session/67942

05/11/2025

🎥 Explore the future of MS treatment in one of the most forward-looking sessions from !

✨ Scientific Session 13: Emergent Therapies in MS and Related Conditions

This session brought together leading experts to present breakthrough findings and next-generation approaches in MS, MOGAD, and NMOSD management.

Key highlights included:

• BTK inhibitors: evidence and expectations — Heinz Wiendl from Universitätsklinikum Freiburg
• RIPK1 inhibitor SAR443820 in MS: biomarker and safety outcomes — Xavier Montalban from CEMCAT (Centre d'Esclerosi Múltiple de Catalunya)
• Fenebrutinib maintains low disease activity in RMS: 2-year FENopta data — Jiwon Oh from University of Toronto

▶️ Watch the replay now: https://ectrims-congress.virtual-meeting.org/programme/session/67942

Not registered yet? Don’t miss the opportunity to access this session and 100+ more featuring world-leading experts and groundbreaking science.

Register today ➡️ https://bit.ly/46rMFZU

03/11/2025

Join our upcoming Clinical Case NeuroWebinar — free registration now open!

In this interactive session, our expert panel will explore one of the most intriguing challenges in MS management:
How should we approach treatment when patients remain clinically and radiologically stable, yet show persistently elevated NfL levels?

🧠 Rina Demjaha from Medizinische Universität Graz will open with a detailed case study of a 40-year-old MS patient who remains clinically stable on platform therapy and shows no new MRI activity, yet presents with consistently elevated serum NfL levels — prompting key questions about treatment adequacy.

🔍 Michael Khalil from Medizinische Universität Graz will then guide us through the decision-making process in such complex situations, discussing the implications of persistent NfL elevation and whether continued monitoring or treatment modification is the best course of action.

💬 Participants will have the opportunity to submit questions and engage in a live exchange with our panelists.

📅 12 November 2025
🕕 18:00-19:00 CET

Register for free via myECTRIMS 👉 https://my.ectrims.eu/webinars/110

31/10/2025

🌱 Ready to take the next step in your career?
Apply now for the 2026 ECTRIMS Fellowship Programmes!
You have until 1 December to send in your application — so there’s still time to perfect it! ➡️ https://ectrims.eu/fellowships

🎓 Clinical Fellowship: Acquire specialised skills, collaborate with academia & industry leaders, and propel your clinical career to new heights.

🎓 Research Fellowship: Lead groundbreaking research, contribute to medical advancements, and become a thought leader in your domain.

🎓 Nurses & AHP Professionals Training: Elevate your expertise, enhance patient care, and open doors to diverse career opportunities.

🎓 MAGNIMS-ECTRIMS Fellowship: Use cutting-edge magnetic resonance techniques to advance your expertise in multiple sclerosis studies.

🎓 MEDEN-ECTRIMS Fellowship: Gain invaluable clinical experience in neuromyelitis optica spectrum disorders ( ) and myelin oligodendrocyte glycoprotein antibody-associated disorder ( ).

30/10/2025

“There’s a lot of attention paid to the physical symptoms of MS... but in terms of mental health, we’re probably still lagging behind.” – Dr. Rebecca MaGuire

🎙️ As we wrap this month’s focus on International Depression Awareness, this episode of the ECTRIMS Podcast shines a light on why mental health — including depression, anxiety, loneliness, and stigma — must be central to conversations about MS care.

Rebecca MaGuire from Maynooth University shares both research insights and her personal experience of living with MS, and shines a spotlight on how clinicians and communities can foster more open, supportive environments for people living with the condition.

🎧 Listen now:

▶️ Spotify https://bit.ly/47OAXcg
▶️ Apple https://apple.co/4qOqQvM

MStranslate

Adresse

Reinacherstrasse 131
Basel
4053

Telefon

+41616867777

Webseite

http://www.ectrims.eu/

Benachrichtigungen

Lassen Sie sich von uns eine E-Mail senden und seien Sie der erste der Neuigkeiten und Aktionen von European Committee for Treatment & Research in Multiple Sclerosis erfährt. Ihre E-Mail-Adresse wird nicht für andere Zwecke verwendet und Sie können sich jederzeit abmelden.